


## AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Previously Presented) A compound comprising at least one moiety of the formula




wherein L<sub>1</sub> is a C<sub>1</sub>-C<sub>4</sub> alkyl group and L<sub>2</sub> is a direct bond, and Aryl<sub>1</sub> and Aryl<sub>2</sub> are aryl, wherein each of Aryl<sub>1</sub> and Aryl<sub>2</sub> are substituted by at least one lipophilic group selected from the group consisting of

- a) -Y-C<sub>1-6</sub> alkyl;
- b) -Y-aryl;
- c) -Y-C<sub>1-6</sub> alkylaryl;
- d) -Y-C<sub>1-6</sub>-alkyl-NR<sub>7</sub>R<sub>8</sub>;
- e) -Y-C<sub>1-6</sub>-alkyl-W-R<sub>20</sub>;

wherein

Y and W are, independently selected from the group consisting of -CH<sub>2</sub>-, -O-, -N(H)-, -S-, SO<sub>2</sub>-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO<sub>2</sub>-, -SO<sub>2</sub>N(H)-, -C(O)-O-, -NHSO<sub>2</sub>NH-, -O-CO-,



and

f) halogen, hydroxyl, cyano, carbamoyl, and carboxyl;


wherein

$R_{18}$  and  $R_{19}$  are independently selected from the group

consisting of aryl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkylaryl,  $C_1$ - $C_6$  alkoxy, and  $C_1$ - $C_6$  alkoxyaryl;

$R_{20}$  is selected from the group consisting of aryl,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkylaryl;

$R_7$ ,  $R_8$ ,  $R_9$  and  $R_{10}$  are independently selected from the group consisting of hydrogen, aryl,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkylaryl; and wherein  $R_7$  and  $R_8$  may be taken together to form a ring having the formula  $-(CH_2)_m-X-(CH_2)_n-$  bonded to the nitrogen atom to which  $R_7$  and  $R_8$  are attached, wherein  $m$  and  $n$  are, independently, 1, 2, 3, or 4;  $X$  is selected from the group consisting of  $-CH_2-$ ,  $-O-$ ,  $-S-$ ,  $-S(O_2)-$ ,  $-C(O)-$ ,  $-CON(H)-$ ,  $-NHC(O)-$ ,  $-NHCON(H)-$ ,  $-NHSO_2-$ ,  $-SO_2N(H)-$ ,  $-C(O)-O-$ ,  $-O-C(O)-$ ,  $-NHSO_2NH-$ ,



or a pharmaceutically acceptable salt thereof,

wherein at least one of  $Aryl_1$  and  $Aryl_2$  is substituted with a lipophilic group of the formula  $-Y-C_{1-6}\text{-alkyl-NR}_7R_8$ .

2. (Previously Presented) The compound of Claim 1, wherein at least one of Aryl<sub>1</sub> or Aryl<sub>2</sub> is further substituted with a lipophilic group selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylaryl, and C<sub>1</sub>-C<sub>6</sub> alkoxyaryl.

Claims 3-10 (Canceled).

11. (Original) A pharmaceutical composition comprising a compound of claim 1 together with one or more pharmaceutically acceptable carriers or diluents.

12. (Original) The pharmaceutical composition of claim 11, in the form of an oral dosage or parenteral dosage unit.

13. (Original) The pharmaceutical composition of claim 11, wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

14. (Original) The pharmaceutical composition of claim 11, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

15. (Original) The pharmaceutical composition of claim 11, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

Claims 16-51 (Canceled).